Monoaspartyl chlorin e6

Base Information

• Chemical Name: Monoaspartyl chlorin e6
• CAS No.: 110230-98-3
• Molecular Formula: C38H41N5O9
• Molecular Weight: 711.76
• ChEMBL ID: CHEMBL1697761
• DSSTox Substance ID: DTXSID70869525
• Metabolomics Workbench ID: 152907
• NCI Thesaurus Code: C90923
• Wikidata: Q7678897
• Wikipedia: Talaporfin
• Mol file: 110230-98-3.mol

Synonyms:laserphyrin;mono-L-aspartyl chlorin e6;monoaspartyl chlorin e6;N-aspartyl chlorin e6;N-aspartylchlorin e6;NPe6;Talaporfin;talaporfin sodium

Chemical Property of Monoaspartyl chlorin e6

Chemical Property:

• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.64
• Boiling Point: 1218.1 °C at 760 mmHg
• Flash Point: 690.5 °C
• PSA: 238.09000
• Density: 1.359 g/cm³
• LogP: 3.52610
• Storage Temp.: -20°C Freezer
• Solubility.: DCM, EA, MeOH
• XLogP3: 3.5
• Hydrogen Bond Donor Count: 7
• Hydrogen Bond Acceptor Count: 11
• Rotatable Bond Count: 12
• Exact Mass: 711.29042790
• Heavy Atom Count: 52
• Complexity: 1360

Purity/Quality:

98%Min ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=O)O)CC(=O)NC(CC(=O)O)C(=O)O)CCC(=O)O)C)C)C=C)C
• Recent NIPH Clinical Trials: Study of the effects of photodynamic therapy for patients with cervical intraepithlial neoplasia on vaginal bacteria
• Description: In collaboration with Light Sciences Corp. and Meiji Seika Kaisha, Nippon Petrochemicals has developed and launched the injectable photosensitizer talaporfin sodium in Japan for the photodynamic therapy (PDT) of cancer. The initial approval is for the treatment of early stage lung cancer, but Light Sciences Corp. and its subsidiaries are also developing talaporfin sodium for other hyperproliferative diseases, such as, liver metastases arising from colorectal cancer, wet age-related macular degeneration, and atherosclerosis. Talaporfin sodium is typically supplied as a lyophilized green powder, and it is synthesized via a carbodiimide-mediated coupling of chlorin e6 (obtained from precursors that were extracted from natural sources) with L-aspartic acid. Since chlorin e6 contains three carboxylic acid groups, the coupling reaction produces a mixture of aspartic acid conjugates. The desired site of conjugation is the acetic acid side chain of C-20, and the other regioisomers are removed by chromatographic purification. Compared to other photosensitizers, talaporfin sodium is associated with minimal cutaneous photosensitivity, is activated at long wavelengths permitting deeper tissue penetration, and requires a shorter interval between intravenous administration and photoactivation. It has a serum half-life of nine hours and is excreted unmetabolized, predominantly by the biliary system. In the clinical study of patients with early lung cancer, a complete response was obtained in approximately 86% of the lesions (administration at 40 mg/m2 followed by laser irradiation at 100 J/cm2, 4–6 hours later). In addition to laser activation, a clinical study involving a variety of refractory solid tumors demonstrated that intratumoral delivery of light-emitting diodes was effective; a 33% overall response rate was observed with no cutaneous phototoxicity. Regardless of the mode of activation, the outcome is the same; the activated photosensitizer reacts with endogenous oxygen to generate singlet oxygen that ultimately leads to apoptosis and vascular ischemia of the targeted tissue. The most significant adverse effect associated with talaporfin sodium was generalized cutaneous photosensitivity, and erythema and oedema were common as well. Individual cases of nausea, vomiting, diarrhea, heartburn, headache, and pruritus were also reported.
• Uses: Talaporfin is a photosensitizer used in photodynamic therapy.